HomeCompareFSTX vs ADC

FSTX vs ADC: Dividend Comparison 2026

FSTX yields 28.09% · ADC yields 4.11%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ADC wins by $58.5K in total portfolio value· pulled ahead in Year 10
10 years
FSTX
FSTX
● Live price
28.09%
Share price
$7.12
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$118.5K
Annual income
$14,804.06
Full FSTX calculator →
ADC
Agree Realty Corporation
● Live price
4.11%
Share price
$75.38
Annual div
$3.10
5Y div CAGR
40.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$176.9K
Annual income
$79,647.25
Full ADC calculator →

Portfolio growth — FSTX vs ADC

📍 ADC pulled ahead of the other in Year 10

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodFSTXADC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, FSTX + ADC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
FSTX pays
ADC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

FSTX
Annual income on $10K today (after 15% tax)
$2,387.64/yr
After 10yr DRIP, annual income (after tax)
$12,583.45/yr
ADC
Annual income on $10K today (after 15% tax)
$349.45/yr
After 10yr DRIP, annual income (after tax)
$67,700.16/yr
At 15% tax rate, ADC beats the other by $55,116.71/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of FSTX + ADC for your $10,000?

FSTX: 50%ADC: 50%
100% ADC50/50100% FSTX
Portfolio after 10yr
$147.7K
Annual income
$47,225.65/yr
Blended yield
31.97%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ADC right now

FSTX
Analyst Ratings
3
Buy
2
Hold
Consensus: Buy
Altman Z
0.7
Piotroski
3/9
ADC
Analyst Ratings
1
Strong
22
Buy
9
Hold
Consensus: Buy
Price Target
$81.06
+7.5% upside vs current
Range: $75.00 — $84.50
Altman Z
1.6
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

FSTX buys
0
ADC buys
0
No recent congressional trades found for FSTX or ADC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricFSTXADC
Forward yield28.09%4.11%
Annual dividend / share$2.00$3.10
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.4%
Portfolio after 10y$118.5K$176.9K
Annual income after 10y$14,804.06$79,647.25
Total dividends collected$78.8K$154.7K
Payment frequencyquarterlymonthly
SectorStockREIT
Analyst consensusBuyBuy

Year-by-year: FSTX vs ADC ($10,000, DRIP)

YearFSTX PortfolioFSTX Income/yrADC PortfolioADC Income/yrGap
1$13,509$2,808.99$10,987$577.21+$2.5KFSTX
2$18,001$3,546.41$12,293$855.34+$5.7KFSTX
3$23,678$4,416.52$14,088$1,290.70+$9.6KFSTX
4$30,764$5,429.21$16,660$1,994.91+$14.1KFSTX
5$39,510$6,592.67$20,525$3,181.85+$19.0KFSTX
6$50,189$7,913.03$26,654$5,286.90+$23.5KFSTX
7$63,097$9,394.15$37,006$9,259.47+$26.1KFSTX
8$78,551$11,037.47$55,862$17,338.74+$22.7KFSTX
9$96,891$12,841.93$93,452$35,300.32+$3.4KFSTX
10← crossover$118,478$14,804.06$176,931$79,647.25$58.5KADC

FSTX vs ADC: Complete Analysis 2026

FSTXStock

F-star Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops tetravalent bispecific antibodies for cancer therapy. Its medicines are used in immuno-oncology treatments. The company's principal product candidate is FS118 and is being evaluated in a proof-of-concept Phase 2 trial in PD-1/PD-L1 acquired resistance head and neck cancer patients. It is also developing first-in-human clinical study of FS222, a bispecific antibody that is in Phase 1 clinical trial targeting the costimulatory CD137 receptor and the inhibitory PD-L1 ligand. In addition, the company is also evaluating FS120 and SB 11285 for patients with advanced cancers, which are under Phase 1 clinical trials. F-star Therapeutics, Inc. was incorporated in 2002 and is headquartered in Cambridge, the United Kingdom.

Full FSTX Calculator →

ADCREIT

Agree Realty Corporation is a publicly traded real estate investment trust primarily engaged in the acquisition and development of properties net leased to industry-leading retail tenants. As of September 30, 2020, the Company owned and operated a portfolio of 1,027 properties, located in 45 states and containing approximately 21.0 million square feet of gross leasable area. The Company's common stock is listed on the New York Stock Exchange under the symbol ADC.

Full ADC Calculator →
📬

Get this FSTX vs ADC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

FSTX vs SCHDFSTX vs JEPIFSTX vs OFSTX vs KOFSTX vs MAINFSTX vs NNNFSTX vs EPRTFSTX vs FCPT

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.